EQOS - VIR VOYA and DBVT among pre market gainers
BiondVax Pharmaceuticals (NASDAQ:BVXV) +55% signs definitive agreements for development and commercialization of innovative nanosized COVID-19 antibody therapy with Max Planck Institute of Biophysical Chemistry and University Medical Center Göttingen, Germany. BioRestorative Therapies (NASDAQ:BRTX) +35%. Red Cat Holdings (OTCQB:RCAT) +35% subsidiary awarded $90M BPA by Customs and Border Protection. Acasti Pharma (NASDAQ:ACST) +24% on new Outperform rating at Oppenheimer with PT of $6. American Virtual Cloud Technologies (NASDAQ:AVCT) +23%. DBV Technologies (NASDAQ:DBVT) +17%. SenesTech (NASDAQ:SNES) +9%. Voya Financial (NYSE:VOYA) +8% set to join S&P MidCap 400. Eqonex (NASDAQ:EQOS) +7%. Context Therapeutics (NASDAQ:CNTX) +7%. Galera Therapeutics (NASDAQ:GRTX) +5%. Vir Biotechnology (NASDAQ:VIR) +5%.
For further details see:
VIR, VOYA and DBVT among pre market gainers